Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.

Christoph R KimmichTobias TerzerAxel BennerTimon HansenAlexander CarpinteiroTobias DittrichKaya VeelkenAnna JauchStefanie HuhnMarco BassetHartmut GoldschmidtCarsten Müller-TidowStefan O SchönlandUte Hegenbart

Published in: American journal of hematology (2021)

Keyphrases

multiple myeloma
high dose

low dose
oxidative stress

stem cell transplantation
newly diagnosed

drug induced